Advancing CDC Projects And Manawa-Contact Merger Will Strengthen Future Infrastructure

AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Published
29 Nov 24
Updated
29 May 25
AnalystConsensusTarget's Fair Value
NZ$10.48
13.0% overvalued intrinsic discount
29 May
NZ$11.84
Loading
1Y
11.2%
7D
1.8%

Author's Valuation

NZ$10.5

13.0% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 0.57%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 22%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.2%.

Shared on17 Apr 25
Fair value Decreased 2.11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 1.03%

AnalystConsensusTarget has increased revenue growth from 0.5% to 4.1%, decreased profit margin from 22.6% to 7.0%, increased future PE multiple from 22.8x to 68.2x and increased discount rate from 7.7% to 8.5%.

Shared on02 Apr 25
Fair value Increased 4.29%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Decreased 0.34%

AnalystConsensusTarget has increased revenue growth from 0.0% to 0.5%, increased profit margin from 4.9% to 22.6% and decreased future PE multiple from 103.9x to 22.8x.